• Share
  • Email
  • Embed
  • Like
  • Save
  • Private Content
Hema core 2013.11.20_en_business_pitch_v8.2_16x9
 

Hema core 2013.11.20_en_business_pitch_v8.2_16x9

on

  • 291 views

 

Statistics

Views

Total Views
291
Views on SlideShare
291
Embed Views
0

Actions

Likes
0
Downloads
0
Comments
0

0 Embeds 0

No embeds

Accessibility

Upload Details

Uploaded via as Microsoft PowerPoint

Usage Rights

© All Rights Reserved

Report content

Flagged as inappropriate Flag as inappropriate
Flag as inappropriate

Select your reason for flagging this presentation as inappropriate.

Cancel
  • Full Name Full Name Comment goes here.
    Are you sure you want to
    Your message goes here
    Processing…
Post Comment
Edit your comment
  • Cardio-vascular diseases - 15 сек <br />
  • Проблема <br /> 20 сек = 1 мин <br />
  • Sales – <br /> 30 сек = 3:30 <br />
  • Команда – <br /> 30 сек = 5:20 <br />
  • Сейчас – <br /> 40 сек = 6:00 <br />
  • Сейчас – <br /> 40 сек = 6:00 <br />
  • Что нужно – <br /> 30 сек = 6:30 <br />
  • Итого – <br /> 30 сек = 7:00 <br />

Hema core 2013.11.20_en_business_pitch_v8.2_16x9 Hema core 2013.11.20_en_business_pitch_v8.2_16x9 Presentation Transcript

  • Hemacore Innovative diagnostics of blood coagulation Igor Pivovarov, CEO 12 Nov 2013
  • cvd – big unmeet need in treatment
  • Why coagulation? • The system, that protects from blood loss • Coagulation disorders: bleeding and thrombosis • Coagulation is a systematic reason of CVD David Lillicrap; Nigel Key; Michael Makris; Denise O'Shaughnessy (2009). Practical Hemostasis and Thrombosis. Wiley-Blackwell. pp. 1–5. ISBN 1-4051-8460-4.
  • ThromboDynamics •New global assay for monitoring and prognosis of blood coagulation disorders – risks of bleeding and thrombosis
  • Thrombodynamics: how it works • Best in-vitro model of in-vivo coagulation process Growing fibrin clot Cuvette (2 channels) Insert Activating insert Immobilized activator (Tissue factor) Blood plasma sample Blood plasma Insert with Tissue factor
  • Our products • Laboratory instrument • Disposable Clinical utility 1.Screening for risk of bleeding or thrombosis 2.Monitoring the efficacy of treatment * Recommended end user prices Confidential
  • Sales AND market Coagulation tests market – $1.8B • Russia ~ $130M (2011*) • USA ~ $586M (2009*) • EU ~ €500M (2006*) Our customer • Research & clinical labs (RUO) • Hospital and clinical labs (IVD) * Data from independent market research
  • Key people Management CEO Igor Pivovarov Operations COO Andrey Kondratovich Sales CCO Sergey Zamakhaev Science CSO Fazly Ataullakhanov Clinical trials CMO Ilya Serebriysky R&D CTO Sergey Karamzin •Physicist, Physics department MSU •Dr. Sc., PhD, Prof. •Moscow State University •Physics department MSU •MBA, IBS Moscow •MD, hematologist •MD, Kem.Med.Ins. •Ph.D, Economist •Ph.D., engineer
  • What is done • 2010.Oct – round A received ~ $18M • 2011.Apr – instrument development finished • 2011.Dec – first clinical trial in Russia finished • 2012.Apr – HemaCore became Skolkovo resident • 2012.Jun – disposables technology finished • 2012.Oct – approval in Russia received • 2012.Nov – sales in Russia started • 2012.Dec – ISO 9001:2008 received • 2013.Feb – Europe office HemaCore SA founded Confidential
  • Latest news • 2013.Mar - Thrombodynamics analyzer won the RedDot Design Award 2013
  • What is next 2013 • Additional clinical trials in Russia for reimbursement 2014 • Multicentral clinical trials in Europe and USA to receive CE and FDA approval 2015 • Reimbursement in Russia 2014 • CE approval in Europe 2016 • FDA approval in USA Confidential
  • What we are looking for • Investments: round B – €10,5M • Goals: CE and FDA approval, reimbursement in Russia • Tasks: clinical trials in Russia/Europe/USA, approval in Europe/USA • Commited: €3M from current investors • Looking for: €7,5M Confidential
  • Thank you for your attention Igor Pivovarov m.+7-903-776-2234 (Russia) m.+41-79-937-7381 (Switzerland) i.pivovarov@hemacore.com www.linkedin.com/in/igorpivovarov Company site: www.hemacore.com Thrombodynamics site: www.thrombodynamics.com
  • appendix
  • 66% 100% 34% Prognosing risks: DVT Within 100% patient group with INR in therapeutic range 2-3 Thrombodynamics: 42% 42% of patients in this group later shows positive dynamics of thrombosis selects a group of 34% patients with high thrombotic risk